Bioavailability evaluation of innovative new formulations for the treatment of breast cancer

治疗乳腺癌的创新新制剂的生物利用度评估

• 批准号: 555380-2020
• 负责人: Fortier, Isabelle
• 金额: $ 1.82万
• 依托单位: C.E.G.E.P. Lévis-Lauzon
• 依托单位国家: 加拿大
• 项目类别: Applied Research and Development Grants - Level 1
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=705606
• 关键词: Bioavailability; evaluation; innovative; new; formulations

Recent studies have highlighted the potential of dugs such as Raloxifene, Letrozole and cannabidiol (CBD) in the prevention and/or treatment of breast cancer. However, like the vast majority of potential new compounds, low aqueous solubility and oral bioavailability hinder the clinical development of effective formulations. Fortunately, such limitations could be overcome using drug delivery agents like hyaluronic acid. HA is an interesting agent as it is a macropolysaccharide naturally present in most tissues and body fluids. On the one hand, it plays important functions in physiologic and pathologic events and on the other it has also been extensively used as a drug carrier. Thus, the combination of HA with drugs like Raloxifene, Letrozole and CBD could lead to an improvement in their pharmacokinetic properties and enhanced their oral bioavailability. The main goal of this project is to determine the pharmacokinetic properties of new molecular complex of Raloxifene and Letrozole with HA alone or in combination with CBD to evaluate their potential in the development of new treatments for breast cancer. Animals will received an oral administration of the HA formulations and plasmatic concentrations will be compared to the naked drug.

最近的研究强调了雷洛昔芬，来曲唑和大麻二酚（CBD）等药物在预防和/或治疗乳腺癌方面的潜力。然而，与绝大多数潜在的新化合物一样，低水溶性和口服生物利用度阻碍了有效制剂的临床开发。幸运的是，使用透明质酸等药物输送剂可以克服这些限制。HA是一种令人感兴趣的试剂，因为它是天然存在于大多数组织和体液中的大多糖。它一方面在生理和病理过程中发挥重要作用，另一方面也被广泛用作药物载体。因此，HA与雷洛昔芬、来曲唑和CBD等药物的组合可以改善其药代动力学特性并提高其口服生物利用度。该项目的主要目标是确定雷洛昔芬和来曲唑与HA单独或与CBD组合的新分子复合物的药代动力学特性，以评估其在开发乳腺癌新治疗方法中的潜力。动物将接受HA制剂的经口给药，并将血浆浓度与裸药物进行比较。